Liver disease quality standard (QS152)

Quality standard · Tier 1, UK official · UK · 2017-06-29

Current — checked with the publisher on 2026-09-01

https://www.nice.org.uk/guidance/qs152

What this platform has drawn from it — 1 claim

NICE recommends offering ultrasound, with or without measurement of serum alpha-fetoprotein, every 6 months as surveillance for hepatocellular carcinoma in people with cirrhosis who do not have hepatitis B virus infection. Quality statement 4: Surveillance for hepatocellular carcinoma
held in the ledger, not rendered on any page

How this record was checked, and what is doubtful about it

Published and last reviewed 29 June 2017. Five quality statements; statement 4 covers HCC surveillance, statement 5 covers prophylactic IV antibiotics for upper GI bleeding. Explicitly does not cover treatment for liver cancer. Endorsed by NHS England; supported by BASL among others.

Verification: verified · last accessed 2026-09-01 · status checked against https://www.nice.org.uk/guidance/qs152